Navigation Links
Masimo to Present at the Deutsche Bank 34th Annual Health Care Conference
Date:5/12/2009

IRVINE, Calif., May 12 /PRNewswire-FirstCall/ -- Masimo Corporation (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced that its management is scheduled to present at the Deutsche Bank 34th Annual Health Care Conference in Boston, Massachusetts, on Tuesday, May 19, 2009, at 2:35 p.m. EDT. A live audiocast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will be available following the live presentation.

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

    Masimo Corporation
    Investor Contact:                             Media Contact:
    Mark P. de Raad                               Dana Banks
    Executive Vice President                      Manager, Public Relations
     and Chief Financial Officer                  Masimo Corporation
    Masimo Corporation                            (949) 297-7348
    (949) 297-7080                                dbanks@masimo.com
    mderaad@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.


'/>"/>
SOURCE Masimo Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
2. Masimo Reports Second Quarter 2007 Financial Results
3. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
4. Masimo to Report Third Quarter 2007 Financial Results on October 30, 2007
5. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
6. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
8. Masimo Announces Continuous Noninvasive Total Hemoglobin
9. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
10. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
11. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... ... of biologics. To acquire information on the desired increase and/or decrease in antibody-dependent ... industry for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Functional near-infrared spectroscopy ... is being explored as a way to track the brain’s response to acute pain ... activation by cold pressor test ,” published today in the journal Neurophotonics , ...
(Date:3/22/2017)... MARLBOROUGH, Mass. , March 22, 2017 /PRNewswire/ ... company developing innovative therapeutics that address significant unmet ... PhD, RXi,s Chief Business Officer, will present at ... The forum will provide a platform to present ... research institutes, leading pharmaceutical and biotech companies as ...
(Date:3/20/2017)... ... 20, 2017 , ... Avexegen Therapeutics Inc., an innovative biotechnology ... entered into an exclusive global license agreement with Children’s Hospital Los Angeles (CHLA) ... orphan disease) as well as Crohn’s Disease and Ulcerative Colitis. , ...
Breaking Biology Technology:
(Date:2/27/2017)... Strategic Cyber Ventures , the industry,s first cybersecurity focused ... investment in  Polarity , the first commercial human memory-augmentation ... and is led by cybersecurity veterans Tom Kellermann ... , also a longtime cybersecurity veteran and founder of ... round of funding. This new funding will be used ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):